The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03)
Open accessAbstract
PURPOSE: SJMB03 (ClinicalTrials.gov identifier: NCT00085202 ) was a phase III risk-adapted trial that aimed to determine the frequency and clinical significance of biological variants and genetic alterations in medulloblastoma. PATIENTS AND METHODS: Patients 3-21 years old were stratified into average-risk and high-risk treatment groups based on metastatic status and extent of resection. Medulloblastomas were molecularly classified into subgroups (Wingless [WNT], Sonic Hedgehog [SHH], group 3, and group 4) and subtypes based on DNA methylation profiles and overlaid with gene mutations from next-generation sequencing. Coprimary study end points were (1) to assess the relationship between ERBB2 protein expression in tumors and progression-free survival (PFS), and (2) to estimate the frequency of mutations associated with WNT and SHH tumors. Clinical and molecular risk factors were evaluated, and the most robust were used to model new risk-classification categories. RESULTS: Three hundred thirty eligible patients with medulloblastoma were enrolled. Five-year PFS was 83.2% (95% CI, 78.4 to 88.2) for average-risk patients (n = 227) and 58.7% (95% CI, 49.8 to 69.1) for high-risk patients (n = 103). No association was found between ERBB2 status and PFS in the overall cohort ( P = .74) or when patients were stratified by clinical risk ( P = .71). Mutations in CTNNB1 (96%), DDX3X (37%), and SMARCA4 (24%) were most common in WNT tumors and PTCH1 (38%), TP53 (21%), and DDX3X (19%) in SHH tumors. Methylome profiling classified 53 WNT (17.4%), 48 SHH (15.7%), 65 group 3 (21.3%), and 139 group 4 (45.6%) tumors. A comprehensive clinicomolecular risk factor analysis identified three low-risk groups (WNT, low-risk SHH, and low-risk combined groups 3 and 4) with excellent (5-year PFS > 90%) and two very high-risk groups (high-risk SHH and high-risk combined groups 3 and 4) with poor survival (5-year PFS < 60%). CONCLUSION: These results establish a new risk stratification for future medulloblastoma trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“we developed the Medulloblastoma Meta-Analysis (MB-meta) portal, which integrates clinical, genomic, and survival data from 898 patients across three major medulloblastoma clinical trials (16–18).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA methylation-based classification of central nervous system tumours
Capper, D., Jones, D., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chávez, L., Reuß, D., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 3,114
Self-citationMolecular subgroups of medulloblastoma: the current consensus
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y.-J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0922-z · Cited by 1,936
Self-citationMedulloblastoma Comprises Four Distinct Molecular Variants
Northcott, P. A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C. G., Mack, S. C., Bouffet, É., Clifford, S. C., Hawkins, C. E., French, P. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4324 · Cited by 1,353
Self-citationIntertumoral Heterogeneity within Medulloblastoma Subgroups
Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.005 · Cited by 1,219
Self-citationThe whole-genome landscape of medulloblastoma subtypes
Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., et al. (2017) · Nature · doi:10.1038/nature22973 · Cited by 1,112
Self-citationPacker, R. J., Gajjar, A. J., Vézina, G., Rorke-Adams, L. B., Burger, P. C., Robertson, P. L., Bayer, L. A., Lafond, D. A., Donahue, B. R., Marymont, M. H., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4980 · Cited by 985
Self-citationGajjar, A. J., Chintagumpala, M., Ashley, D. M., Kellie, S. J., Kun, L. E., Merchant, T. E., Woo, S. Y., Wheeler, G., Ahern, V., Krasin, M. J., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70867-1 · Cited by 951
Self-citationSubgroup-specific structural variation across 1,000 medulloblastoma genomes
Northcott, P. A., Shih, D. J. H., Peacock, J., Garzia, L., Morrissy, A. S., Zichner, T., Stütz, A. M., Korshunov, A., Reimand, J., Schumacher, S. E., et al. (2012) · Nature · doi:10.1038/nature11327 · Cited by 887
Self-citationRausch, T., Jones, D. T. W., Zapatka, M., Stütz, A. M., Zichner, T., Weischenfeldt, J., Jäger, N., Remke, M., Shih, D., Northcott, P. A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.013 · Cited by 865
Self-citationNovel mutations target distinct subgroups of medulloblastoma
Robinson, G. W., Parker, M. D., Kranenburg, T. A., Lu, C., Chen, X. '., Ding, L., Phoenix, T. N., Hedlund, E., Wei, L., Zhu, X., et al. (2012) · Nature · doi:10.1038/nature11213 · Cited by 853
Self-citationGenome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition
Kool, M., Jones, D., Jäger, N., Northcott, P. A., Pugh, T. J., Hovestadt, V., Piro, R. M., Esparza, L. A., Markant, S. L., Remke, M., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.004 · Cited by 756
Self-citationEllison, D. W., Onilude, O. E., Lindsey, J. C., Lusher, M. E., Weston, C. L., Taylor, R. E., Pearson, A. D. J., & Clifford, S. C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5479 · Cited by 434
Self-citationResolving medulloblastoma cellular architecture by single-cell genomics
Hovestadt, V., Smith, K. S., Bihannic, L., Filbin, M. G., Shaw, M. L., Baumgartner, A., DeWitt, J. C., Groves, A. P., Mayr, L., Weisman, H. R., et al. (2019) · Nature · doi:10.1038/s41586-019-1434-6 · Cited by 392
Self-citationThompson, E. M., Hielscher, T., Bouffet, É., Remke, M., Luu, B., Gururangan, S., McLendon, R. E., Bigner, D. D., Lipp, E., Perreault, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00581-1 · Cited by 367
Self-citationLannering, B., Rutkowski, S., Doz, F., Pizer, B. L., Gustafsson, G., Navajas, A., Massimino, M., Reddingius, R. E., Benesch, M., Carrié, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8719 · Cited by 332
Cytogenetic Prognostication Within Medulloblastoma Subgroups
Shih, D. J. H., Northcott, P. A., Remke, M., Korshunov, A., Ramaswamy, V., Kool, M., Luu, B., Yao, Y., Wang, X., Dubuc, A. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9539 · Cited by 315
Self-citationHistopathologic grading of medulloblastomas
Eberhart, C. G., Kepner, J. L., Goldthwaite, P. T., Kun, L. E., Duffner, P. K., Friedman, H. S., Strother, D. R., & Burger, P. C. (2002) · Cancer · doi:10.1002/cncr.10189 · Cited by 314
Sharma, T., Schwalbe, E. C., Williamson, D., Sill, M., Hovestadt, V., Mynarek, M., Rutkowski, S., Robinson, G. W., Gajjar, A., Cavalli, F., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02020-0 · Cited by 310
Self-citationEllison, D. W., Kocak, M., Dalton, J., Megahed, H., Lusher, M. E., Ryan, S. L., Zhao, W., Nicholson, S. L., Taylor, R. E., Bailey, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2810 · Cited by 302
Self-citationHovestadt, V., Remke, M., Kool, M., Pietsch, T., Northcott, P. A., Fischer, R., Cavalli, F. M. G., Ramaswamy, V., Zapatka, M., Reifenberger, G., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1126-5 · Cited by 292
Self-citationGajjar, A., Hernan, R., Kocak, M., Fuller, C., Lee, Y., McKinnon, P. J., Wallace, D., Lau, C., Chintagumpala, M., Ashley, D. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.032 · Cited by 279
Self-citationMedulloblastomics revisited: biological and clinical insights from thousands of patients
Hovestadt, V., Ayrault, O., Swartling, F. J., Robinson, G. W., Pfister, S. M., & Northcott, P. A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0223-8 · Cited by 271
Self-citationHistopathological and Molecular Prognostic Markers in Medulloblastoma
Eberhart, C. G., Kratz, J., Wang, Y., Summers, K., Stearns, D. S., Cohen, K. J., Dang, C. V., & Burger, P. C. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.5.441 · Cited by 217
Jakacki, R. I., Burger, P. C., Zhou, T., Holmes, E. J., Koçak, M., Onar, A., Goldwein, J. L., Mehta, M. P., Packer, R. J., Tarbell, N. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.2792 · Cited by 216
von Bueren, A. O., Kortmann, R., von Hoff, K., Friedrich, C., Mynarek, M., Müller, K., Goschzik, T., Mühlen, A. Z., Gerber, N. U., Warmuth‐Metz, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2428 · Cited by 188
Self-citationGermline Elongator mutations in Sonic Hedgehog medulloblastoma
Waszak, S. M., Robinson, G. W., Gudenas, B. L., Smith, K. S., Forget, A., Kojic, M., García-López, J., Hadley, J. L., Hamilton, K. V., Indersie, É., et al. (2020) · Nature · doi:10.1038/s41586-020-2164-5 · Cited by 170
Self-citationMcManamy, C. S., Pears, J., Weston, C. L., Hanzely, Z., Ironside, J. W., Taylor, R. E., Grundy, R. G., Clifford, S. C., & Ellison, D. W. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00058.x · Cited by 144
Self-citationGilbertson, R. J., Clifford, S. C., MacMeekin, W., Wright, C., Perry, R., Kelly, P., Pearson, A. D. J., & Lunec, J. (1998) · PubMed · doi:10.25405/ncl.34591221 · Cited by 100
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Gilbertson RJ, 1998, Cancer Res, 58, 3932
Cited by
Sorted by citations
Horbinski, C., Berger, T., Packer, R. J., & Wen, P. Y. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00679-w · Cited by 312
Serial assessment of measurable residual disease in medulloblastoma liquid biopsies
Liu, A. P. Y., Smith, K. S., Kumar, R., Paul, L., Bihannic, L., Lin, T., Maaß, K. K., Pajtler, K. W., Chintagumpala, M., Su, J. M. F., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.012 · Cited by 177
Self-citationUnified rhombic lip origins of group 3 and group 4 medulloblastoma
Smith, K. S., Bihannic, L., Gudenas, B. L., Haldipur, P., Tao, R., Gao, Q., Li, Y., Aldinger, K. A., Iskusnykh, I. Y., Chizhikov, V. V., et al. (2022) · Nature · doi:10.1038/s41586-022-05208-9 · Cited by 168
Self-citationEhrhardt, M. J., Krull, K. R., Bhakta, N. H., Liu, Q., Yasui, Y., Robison, L. L., & Hudson, M. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00802-w · Cited by 133
Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma
Kumar, R., Smith, K. S., Deng, M. Y., Terhune, C., Robinson, G. W., Orr, B. A., Liu, A. P. Y., Lin, T., Billups, C. A., Chintagumpala, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01359 · Cited by 86
Self-citation
Metadata
- Authors
- Gajjar, A., Robinson, G. W., Smith, K. S., Lin, T., Merchant, T. E., Chintagumpala, M., Mahajan, A., Su, J., Bouffet, E., Bartels, U., Schechter, T., Hassall, T., Robertson, T., Nicholls, W., Gururangan, S., Schroeder, K., Sullivan, M., Wheeler, G., Hansford, J. R., Kellie, S. J., McCowage, G., Cohn, R., Fisher, M. J., Krasin, M. J., Stewart, C. F., Broniscer, A., Buchhalter, I., Tatevossian, R. G., Orr, B. A., Neale, G., Klimo, P., Boop, F., Srinivasan, A., Pfister, S. M., Gilbertson, R. J., Onar-Thomas, A., Ellison, D. W., & Northcott, P. A.
- Affiliations
- St. Jude Children's Research Hospital (US)
- Baylor College of Medicine (US)
- Mayo Clinic (US)
- Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON
- University of Toronto (CA)
- The University of Queensland (AU)
- UF Health Shands Hospital (US)
- Duke University (US)
- Royal Children's Hospital (AU)
- The University of Melbourne (AU)
- The University of Sydney (AU)
- UNSW Sydney (AU)
- Children's Hospital of Philadelphia (US)
- University of Pittsburgh (US)
- German Cancer Research Center (DE)
- Hartwell Center, St Jude Children's Research Hospital, Memphis, TN
- University of Tennessee Health Science Center (US)
- Cancer Research UK (GB)
- Department of Radiation Oncology, St Jude Children's Research Hospital, Memphis, TN
- ORCID
- Gajjar, Amar
- Robinson, Giles W.
- Smith, Kyle S.
- Lin, Tong
- Merchant, Thomas E.
- Chintagumpala, Murali
- Mahajan, Anita
- Su, Jack
- Bouffet, Eric
- Bartels, Ute
- Schechter, Tal
- Hassall, Tim
- Robertson, Thomas
- Nicholls, Wayne
- Gururangan, Sridharan
- Schroeder, Kristin
- Sullivan, Michael
- Hansford, Jordan R.
- McCowage, Geoffrey
- Cohn, Richard
- Fisher, Michael J.
- Krasin, Matthew J.
- Stewart, Clinton F.
- Broniscer, Alberto
- Buchhalter, Ivo
- Tatevossian, Ruth G.
- Orr, Brent A.
- Neale, Geoff
- Klimo, Paul
- Boop, Frederick
- Srinivasan, Ashok
- Pfister, Stefan M.
- Gilbertson, Richard J.
- Ellison, David W.
- Northcott, Paul A.
- Venue
- Journal of Clinical Oncology
- Published
- 2021-03-01
- Volume
- 39
- Issue
- 7
- Pages
- 822-835
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC10166353
- OpenAlex
- W3118854714
- Cited by
- 241
- References
- 28
- Citations by year
- 2026: 33 · 2025: 63 · 2024: 38 · 2023: 52 · 2022: 33 · 2021: 21
- FWCI
- 20.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Funders
- AstraZeneca
- Cancer Research UK (26398)
- Brain Tumour Charity (GN-000575)
- Genentech
- National Cancer Institute (P30CA021765)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- medulloblastoma, risk-adapted treatment, molecular classification, Group 3 medulloblastoma, Group 4 medulloblastoma, DNA methylation profiling, CTNNB1 mutation, PTCH1 mutation, TP53 mutation, SMARCA4 mutation, progression-free survival, pediatric brain tumors
- MeSH terms
- Progression-Free Survival, Epigenome, Adolescent, Cerebellar Neoplasms, Child, Child, Preschool, DNA Mutational Analysis, Female, Humans, Magnetic Resonance Imaging, Male, Medulloblastoma, Mutation, Predictive Value of Tests, Risk Factors, Time Factors, Biomarkers, Tumor, Risk Assessment, DNA Methylation, Young Adult, Epigenomics, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
